

**This Page Is Inserted by IFW Operations
and is not a part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- **BLACK BORDERS**
- **TEXT CUT OFF AT TOP, BOTTOM OR SIDES**
- **FADED TEXT**
- **ILLEGIBLE TEXT**
- **SKEWED/SLANTED IMAGES**
- **COLORED PHOTOS**
- **BLACK OR VERY BLACK AND WHITE DARK PHOTOS**
- **GRAY SCALE DOCUMENTS**

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ³ : C12N 7/06; G01N 33/54	A1	(11) International Publication Number: WO 84/ 04327 (43) International Publication Date: 8 November 1984 (08.11.84)
(21) International Application Number: PCT/US84/00561 (22) International Filing Date: 13 April 1984 (13.04.84) (31) Priority Application Number: 489,187 (32) Priority Date: 27 April 1983 (27.04.83) (33) Priority Country: US (71) Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGE [US/US]; 17 Quincy Street, Cambridge, MA 02138 (US). (72) Inventors: ESSEX, Myron, E. ; 742 Mountain Street, Sharon, MA 02356 (US). LEE, Tun-Hou ; 80 Farina Road, Newton, MA 02159 (US). (74) Agent: FURLONG, Robert, W.; Fish & Richardson, 28 State Street, Suite 2100, Boston, MA 02109 (US).	(81) Designated States: AT (European patent), AU, BE (European patent), CH (European patent), DE (European patent), DK, FI, FR (European patent), GB (European patent), JP, LU (European patent), NL (European patent), NO, SE (European patent). Published With international search report. , G01N 33/543 , G01N 33/546	

(54) Title: METHOD AND PRODUCTS FOR DETECTION OF HUMAN T CELL LEUKEMIA VIRUS

(57) Abstract

A first glycoprotein having a molecular weight of approximately 61,000-68,000 daltons in the MJ, C5-MJ, C91 PL or HUT-102 cell lines, of which 46,000 to 48,000 is the unglycosylated moiety, is obtained from cells infected with human T cell leukemia virus. A second glycoprotein having a molecular weight of approximately 45,000-52,000 daltons is also obtained from such cells and is in large part identical to the NH₂-terminal end of the first glycoprotein. The presence, in a biological specimen, of antibody to the antigenic determinant of either of these proteins is indicative of the presence of cells infected by human T cell leukemia virus. An assay for the antibody is a useful diagnostic procedure for determining such infection in biological specimens.

Human T cell leukemia virus
is HTLV III

1 A

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ER	Republic of Corea
AU	Australia	LI	Liechtenstein
BE	Belgium	LE	Sri Lanka
BG	Bulgaria	LU	Luxembourg
BR	Brazil	MC	Monaco
CF	Central African Republic	MG	Madagascar
CG	Congo	MR	Mauritania
CH	Switzerland	MY	Malawi
CM	Cameroon	NL	Netherlands
DE	Germany, Federal Republic of	NO	Norway
DK	Denmark	RO	Romania
FI	Finland	SD	Sudan
FR	France	SE	Sweden
GA	Gabon	SN	Senegal
GB	United Kingdom	SU	Soviet Union
HU	Hungary	TD	Chad
JP	Japan	TO	Togo
KP	Democratic People's Republic of Korea	US	United States of America

- 1 -

METHOD AND PRODUCTS FOR DETECTION OF
HUMAN T CELL LEUKEMIA VIRUS

This invention relates to a novel purified forms of glycoprotein found in the cell surface membrane of cells infected with human T cell leukemia virus, and to an assay for detecting in a biological specimen the presence of an antibody to the antigenic determinants present in said glycoproteins.

The human T cell leukemia virus (HTLV) is known to be closely associated with a particular type of human leukemia, the T cell type in adults. It has also been shown that all people whose bodies contain antibodies to this virus are apparently latently infected with the virus. Essex, J.N.C.I., Vol. 69, 981-5 (1982). The major core proteins of the virus have been studied and an immunofluorescent assay procedure for antibodies to the infected cells has been described which involves fixing cells from a cell line of infected human cells such as MT1 or MT2, contacting the fixed cells with the test serum to be assayed, and determining whether bonding of the serum to the cell surface has occurred by subsequently contacting with a fluorescent-labelled antibody to human IgG. Hinuma et al., Proc.Natl.Acad.Sci., Vol. 78, 6476-6480 (1981). This assay is tedious and difficult to use because only 1 to 5% of the fixed cells display the necessary antigenic characteristics. It has also been proposed to employ a somewhat analogous cell surface immunofluorescent assay in which a culture of infected



- 2 -

cells is incubated with test serum, then with fluorescent-labelled rabbit antibody to human IgG to determine whether bonding of serum to cells has occurred. Robert-Guroff et al., Science, Vol. 215, 975-978 (1982). A radioimmunoassay for antibodies to p24 and p19, two of the core proteins of HTLV, has also been described. Posner et al., J.Exp.Med., Vol. 154, 333-344 (1981). However, this assay fails to produce positive results for all individuals who have been exposed to the infecting virus and are therefore at risk, but who do not have detectable levels of antibodies to these two antigens.

Summary of the Invention

It has now been found that particular polypeptides or glycoproteins present on the cell surface of human T cells infected with HTLV when purified and isolated contain an antigenic determinant or determinants which provide a high degree of sensitivity and immunospecificity for antibody to human cells infected with HTLV, to human T cell leukemia cells, and/or to HTLV. Consequently, the substantially pure glycoproteins or their unglycosylated moieties are useful as a diagnostic tool for assaying biological specimens to determine whether they contain cells which have been infected by HTLV. Other polypeptides containing immunologically cross-reactive antigenic determinants are useful for the same purpose. By "polypeptides containing immunologically cross-reactive antigenic determinants" is meant polypeptides having in common antigenic determinants with which a given antibody will react. Such other polypeptides include the unglycosylated moieties of the glycoproteins. Other useful polypeptides or proteins, which have the

- 3 -

necessary immunogenic determinants, include synthetic polypeptides. They also include antibodies or fragments thereof which are anti-idiotypic towards the active determinant or determinants on the glycoprotein of the invention. It has recently been shown that anti-idiotypic monoclonal antibodies can induce an immune response against, and protect against infection by infectious organisms carrying antigenic determinants which are the same or substantially the same as those on the anti-idiotypic antibodies (Fields et al., Nature, 300:19-23 (1982); Sacks et al., J.Exp.Med. 4:1108-1119 (1982)). It has also been shown that anti-idiotypic reagents are useful as diagnostic tools for the detection of antigens carrying sites which are immunologically cross-reactive with those on the antibodies (Potocnjak et al., Science 215: 1637-1639 (1982) herein incorporated by reference). Thus, an assay for HTLV could be carried out with the aid of a anti-idiotypic antibody or immunologically active fragment thereof which carries an antigenic site or sites thereon which are immunologically similar to the antigenic site or sites on the glycoprotein of the invention. Such anti-idiotypic antibodies can be raised against first antibodies having specificity against the antigenic sites on the glycoprotein of the invention (i.e. the anti-idiotypic antibodies are anti-antibodies). Preferably monoclonal anti-idiotypic antibodies are used.

use of anti-idiotypic Ab or frag "an antigen"

An assay for HTLV infection is important because the virus can be readily transferred from the peripheral blood leukocytes of antibody-positive people to leukocytes of antibody-negative people when the two are cultivated together. Popovic et al., Science,



- 4 -

Vol. 219, 856-859 (1983). Consequently, it appears that there is great risk of infection involved in whole blood transfusions when the transfused blood contains infected cells. In addition, the assay is of importance because biological specimens from individuals exhibiting acquired immunodeficient syndrome (AIDS) also give a positive test for antibodies to the antigenic determinant of the novel glycoprotein, thus facilitating diagnosis of that disease.

Consequently, the invention also embraces the method of assaying a biological specimen for the presence of antibody to HTLV-infected cells which comprises incubating said specimen with a polypeptide having an antigenic determinant or determinants immunologically cross-reactive with those of a glycoprotein having a molecular weight of approximately 61,000-68,000 daltons, of which approximately 46-48,000 daltons is the unglycosylated moiety, or with a glycoprotein having a molecular weight of approximately 45,000 to 52,000 daltons, which glycoproteins occur on the cell surface of cells infected with HTLV, and determining whether or not an immunocomplex is formed between said antibody and said polypeptide.

The invention also embraces a method of assaying a biological specimen for the presence of antigenic determinant or determinants immunologically cross-reactive with the determinants of the glycoproteins of molecular weight 61,000-68,000 daltons, or 45,000-52,000 daltons. The determinants to be assayed may occur on the stated glycoproteins themselves or on other polypeptides. They may be in free circulation in the body fluids or in lymphocytes.

- 5 -

The assay can be carried out by known immunoassay methods, using antibodies, monoclonal or polyvalent, having immune reactivity with the antigenic determinants found on the stated glycoproteins. For example competitive immunoassays or immunometric (sandwich) assays can be used.

The glycoproteins of the present invention have a molecular weight of approximately 61,000-68,000 daltons and approximately 45,000-52,000 daltons as determined by sodium dodecyl sulfate (SDS) gel electrophoresis and are soluble in SDS buffer consisting of 0.15 M sodium chloride, 0.05 M Tris hydrochloride pH 7.2, 1% Triton X-100, 1% sodium deoxycholate, 0.1% sodium dodecylsulfate, and 1 mM phenylmethylsulfonyl fluoride. Triton X-100 is a nonionic detergent (octylphenoxy polyethoxy (9-10) ethanol). The unglycosylated moiety of the 61,000-68,000 d glycoprotein has a molecular weight of approximately 46,000-48,000 daltons and contains substantially the same antigenic determinant or determinants as does the glycoprotein itself.

The glycoproteins can be obtained from HTLV-infected cells. A variety of cell lines have been prepared, which are permanently and persistently infected with HTLV; among them can be mentioned MJ, C5-MJ, C91PL, and HUT-102. It may be that the exact sizes of the novel glycoproteins are slightly different in different lines; however, the common immunologically cross-reactive portion of the glycoproteins is the same regardless of cell line, since it is a protein induced by HTLV. Thus, any cell which harbors the virus may be an appropriate source for the novel glycoproteins. In order to obtain the protein from any infected cells



- 6 -

carrying the virus, the cells are metabolically labelled (e.g. with ^{35}S -methionine) and immunoprecipitated with antisera obtained from HTLV infected subjects. The novel glycoproteins can then be detected and isolated by gel electrophoresis. By "HTLV" as used in the present specification and claims it is meant to include the virus generically. Thus any and all forms, subtypes, or variations of the virus are included.

For example, the glycoproteins are present at the cell surfaces of the human T cell leukemia cell cultures MJ, C5-MJ, C91PL and HUT-102. A specimen of MJ and of C5-MJ have been deposited with the American Type Culture Collection on April 26, 1983 as ATCC Nos. CRL-8294 and CRL-8293, respectively. The glycoproteins can readily be separated from the cells of these cell lines by lysis thereof and SDS gel electrophoresis.

The purified and isolated glycoproteins or any antigen immunologically cross-reactive therewith can be employed as a standard antigen in any conventional assay procedure for detection in biological specimens of the presence of antibodies specific thereto, hence of the presence in the specimen of cells infected with HTLV and/or symptomatic of AIDS. The antibodies specific to such HTLV antigens are not found in patients suffering from diseases such as hepatitis which are not accompanied by HTLV infection.

The glycoproteins or polypeptides immunologically cross-reactive therewith can be labelled by conventional procedures with ^{125}I or ^{35}S or ^3H for use in radioimmunoassay, with fluorescein for fluorescent immunoassay, with enzyme for enzyme immunoassay or with biotin, for



- 7 -

biotin-avidin linked assays. It can be employed, labelled or unlabelled as desired, in competitive immunoassays, as well as in double antibody assays using two antibodies, either of the idiotype:anti-
5 idiotype variety or more particularly of the second antibody type using an anti-Fc antibody, or other assays.

Alternatively, the novel glycoproteins or polypeptides immunologically cross-reactive therewith
10 could be immobilized on an insoluble phase, such as an insoluble resin, and detection of the anti-glycoprotein antibodies is carried out by measuring their binding to the insoluble phase. Insoluble phases also include latex particles, which, when coated with the novel
15 glycoprotein or its immunologically cross-reactive polypeptides and subjected to anti-glycoprotein antibody, will agglutinate. Yet other insoluble phases include test tubes, vials, titration wells, and the like, to which the novel glycoprotein or its
20 immunologically cross-reactive polypeptide can be bound, and antibody thereto detected by double antibody techniques or Protein-A dependent techniques.

The assay for antibody to HTLV may utilize the glycoprotein or glycoproteins of m.w. 61-68,000 and
25 46-52,000, respectively, in crude form, and is not limited to using these proteins in substantially pure form. For example, the glycoprotein(s) may be first substantially purified and then mixed together. Alternatively cruder mixtures can also be used. In one
30 embodiment, the assay for the presence of antibodies against HTLV may include detection of additional antibodies in the specimen such as those against HTLV core proteins p19, p24 or a mixture of both of the

5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
105
110
115
120
125
130
135
140
145
150
155
160
165
170
175
180
185
190
195
200
205
210
215
220
225
230
235
240
245
250
255
260
265
270
275
280
285
290
295
300
305
310
315
320
325
330
335
340
345
350
355
360
365
370
375
380
385
390
395
400
405
410
415
420
425
430
435
440
445
450
455
460
465
470
475
480
485
490
495
500
505
510
515
520
525
530
535
540
545
550
555
560
565
570
575
580
585
590
595
600
605
610
615
620
625
630
635
640
645
650
655
660
665
670
675
680
685
690
695
700
705
710
715
720
725
730
735
740
745
750
755
760
765
770
775
780
785
790
795
800
805
810
815
820
825
830
835
840
845
850
855
860
865
870
875
880
885
890
895
900
905
910
915
920
925
930
935
940
945
950
955
960
965
970
975
980
985
990
995
1000
1005
1010
1015
1020
1025
1030
1035
1040
1045
1050
1055
1060
1065
1070
1075
1080
1085
1090
1095
1100
1105
1110
1115
1120
1125
1130
1135
1140
1145
1150
1155
1160
1165
1170
1175
1180
1185
1190
1195
1200
1205
1210
1215
1220
1225
1230
1235
1240
1245
1250
1255
1260
1265
1270
1275
1280
1285
1290
1295
1300
1305
1310
1315
1320
1325
1330
1335
1340
1345
1350
1355
1360
1365
1370
1375
1380
1385
1390
1395
1400
1405
1410
1415
1420
1425
1430
1435
1440
1445
1450
1455
1460
1465
1470
1475
1480
1485
1490
1495
1500
1505
1510
1515
1520
1525
1530
1535
1540
1545
1550
1555
1560
1565
1570
1575
1580
1585
1590
1595
1600
1605
1610
1615
1620
1625
1630
1635
1640
1645
1650
1655
1660
1665
1670
1675
1680
1685
1690
1695
1700
1705
1710
1715
1720
1725
1730
1735
1740
1745
1750
1755
1760
1765
1770
1775
1780
1785
1790
1795
1800
1805
1810
1815
1820
1825
1830
1835
1840
1845
1850
1855
1860
1865
1870
1875
1880
1885
1890
1895
1900
1905
1910
1915
1920
1925
1930
1935
1940
1945
1950
1955
1960
1965
1970
1975
1980
1985
1990
1995
2000
2005
2010
2015
2020
2025
2030
2035
2040
2045
2050
2055
2060
2065
2070
2075
2080
2085
2090
2095
2100
2105
2110
2115
2120
2125
2130
2135
2140
2145
2150
2155
2160
2165
2170
2175
2180
2185
2190
2195
2200
2205
2210
2215
2220
2225
2230
2235
2240
2245
2250
2255
2260
2265
2270
2275
2280
2285
2290
2295
2300
2305
2310
2315
2320
2325
2330
2335
2340
2345
2350
2355
2360
2365
2370
2375
2380
2385
2390
2395
2400
2405
2410
2415
2420
2425
2430
2435
2440
2445
2450
2455
2460
2465
2470
2475
2480
2485
2490
2495
2500
2505
2510
2515
2520
2525
2530
2535
2540
2545
2550
2555
2560
2565
2570
2575
2580
2585
2590
2595
2600
2605
2610
2615
2620
2625
2630
2635
2640
2645
2650
2655
2660
2665
2670
2675
2680
2685
2690
2695
2700
2705
2710
2715
2720
2725
2730
2735
2740
2745
2750
2755
2760
2765
2770
2775
2780
2785
2790
2795
2800
2805
2810
2815
2820
2825
2830
2835
2840
2845
2850
2855
2860
2865
2870
2875
2880
2885
2890
2895
2900
2905
2910
2915
2920
2925
2930
2935
2940
2945
2950
2955
2960
2965
2970
2975
2980
2985
2990
2995
3000
3005
3010
3015
3020
3025
3030
3035
3040
3045
3050
3055
3060
3065
3070
3075
3080
3085
3090
3095
3100
3105
3110
3115
3120
3125
3130
3135
3140
3145
3150
3155
3160
3165
3170
3175
3180
3185
3190
3195
3200
3205
3210
3215
3220
3225
3230
3235
3240
3245
3250
3255
3260
3265
3270
3275
3280
3285
3290
3295
3300
3305
3310
3315
3320
3325
3330
3335
3340
3345
3350
3355
3360
3365
3370
3375
3380
3385
3390
3395
3400
3405
3410
3415
3420
3425
3430
3435
3440
3445
3450
3455
3460
3465
3470
3475
3480
3485
3490
3495
3500
3505
3510
3515
3520
3525
3530
3535
3540
3545
3550
3555
3560
3565
3570
3575
3580
3585
3590
3595
3600
3605
3610
3615
3620
3625
3630
3635
3640
3645
3650
3655
3660
3665
3670
3675
3680
3685
3690
3695
3700
3705
3710
3715
3720
3725
3730
3735
3740
3745
3750
3755
3760
3765
3770
3775
3780
3785
3790
3795
3800
3805
3810
3815
3820
3825
3830
3835
3840
3845
3850
3855
3860
3865
3870
3875
3880
3885
3890
3895
3900
3905
3910
3915
3920
3925
3930
3935
3940
3945
3950
3955
3960
3965
3970
3975
3980
3985
3990
3995
4000
4005
4010
4015
4020
4025
4030
4035
4040
4045
4050
4055
4060
4065
4070
4075
4080
4085
4090
4095
4100
4105
4110
4115
4120
4125
4130
4135
4140
4145
4150
4155
4160
4165
4170
4175
4180
4185
4190
4195
4200
4205
4210
4215
4220
4225
4230
4235
4240
4245
4250
4255
4260
4265
4270
4275
4280
4285
4290
4295
4300
4305
4310
4315
4320
4325
4330
4335
4340
4345
4350
4355
4360
4365
4370
4375
4380
4385
4390
4395
4400
4405
4410
4415
4420
4425
4430
4435
4440
4445
4450
4455
4460
4465
4470
4475
4480
4485
4490
4495
4500
4505
4510
4515
4520
4525
4530
4535
4540
4545
4550
4555
4560
4565
4570
4575
4580
4585
4590
4595
4600
4605
4610
4615
4620
4625
4630
4635
4640
4645
4650
4655
4660
4665
4670
4675
4680
4685
4690
4695
4700
4705
4710
4715
4720
4725
4730
4735
4740
4745
4750
4755
4760
4765
4770
4775
4780
4785
4790
4795
4800
4805
4810
4815
4820
4825
4830
4835
4840
4845
4850
4855
4860
4865
4870
4875
4880
4885
4890
4895
4900
4905
4910
4915
4920
4925
4930
4935
4940
4945
4950
4955
4960
4965
4970
4975
4980
4985
4990
4995
5000
5005
5010
5015
5020
5025
5030
5035
5040
5045
5050
5055
5060
5065
5070
5075
5080
5085
5090
5095
5100
5105
5110
5115
5120
5125
5130
5135
5140
5145
5150
5155
5160
5165
5170
5175
5180
5185
5190
5195
5200
5205
5210
5215
5220
5225
5230
5235
5240
5245
5250
5255
5260
5265
5270
5275
5280
5285
5290
5295
5300
5305
5310
5315
5320
5325
5330
5335
5340
5345
5350
5355
5360
5365
5370
5375
5380
5385
5390
5395
5400
5405
5410
5415
5420
5425
5430
5435
5440
5445
5450
5455
5460
5465
5470
5475
5480
5485
5490
5495
5500
5505
5510
5515
5520
5525
5530
5535
5540
5545
5550
5555
5560
5565
5570
5575
5580
5585
5590
5595
5600
5605
5610
5615
5620
5625
5630
5635
5640
5645
5650
5655
5660
5665
5670
5675
5680
5685
5690
5695
5700
5705
5710
5715
5720
5725
5730
5735
5740
5745
5750
5755
5760
5765
5770
5775
5780
5785
5790
5795
5800
5805
5810
5815
5820
5825
5830
5835
5840
5845
5850
5855
5860
5865
5870
5875
5880
5885
5890
5895
5900
5905
5910
5915
5920
5925
5930
5935
5940
5945
5950
5955
5960
5965
5970
5975
5980
5985
5990
5995
6000
6005
6010
6015
6020
6025
6030
6035
6040
6045
6050
6055
6060
6065
6070
6075
6080
6085
6090
6095
6100
6105
6110
6115
6120
6125
6130
6135
6140
6145
6150
6155
6160
6165
6170
6175
6180
6185
6190
6195
6200
6205
6210
6215
6220
6225
6230
6235
6240
6245
6250
6255
6260
6265
6270
6275
6280
6285
6290
6295
6300
6305
6310
6315
6320
6325
6330
6335
6340
6345
6350
6355
6360
6365
6370
6375
6380
6385
6390
6395
6400
6405
6410
6415
6420
6425
6430
6435
6440
6445
6450
6455
6460
6465
6470
6475
6480
6485
6490
6495
6500
6505
6510
6515
6520
6525
6530
6535
6540
6545
6550
6555
6560
6565
6570
6575
6580
6585
6590
6595
6600
6605
6610
6615
6620
6625
6630
6635
6640
6645
6650
6655
6660
6665
6670
6675
6680
6685
6690
6695
6700
6705
6710
6715
6720
6725
6730
6735
6740
6745
6750
6755
6760
6765
6770
6775
6780
6785
6790
6795
6800
6805
6810
6815
6820
6825
6830
6835
6840
6845
6850
6855
6860
6865
6870
6875
6880
6885
6890
6895
6900
6905
6910
6915
6920
6925
6930
6935
6940
6945
6950
6955
6960
6965
6970
6975
6980
6985
6990
6995
7000
7005
7010
7015
7020
7025
7030
7035
7040
7045
7050
7055
7060
7065
7070
7075
7080
7085
7090
7095
7100
7105
7110
7115
7120
7125
7130
7135
7140
7145
7150
7155
7160
7165
7170
7175
7180
7185
7190
7195
7200
7205
7210
7215
7220
7225
7230
7235
7240
7245
7250
7255
7260
7265
7270
7275
7280
7285
7290
7295
7300
7305
7310
7315
7320
7325
7330
7335
7340
7345
7350
7355
7360
7365
7370
7375
7380
7385
7390
7395
7400
7405
7410
7415
7420
7425
7430
7435
7440
7445
7450
7455
7460
7465
7470
7475
7480
7485
7490
7495
7500
7505
7510
7515
7520
7525
7530
7535
7540
7545
7550
7555
7560
7565
7570
7575
7580
7585
7590
7595
7600
7605
7610
7615
7620
7625
7630
7635
7640
7645
7650
7655
7660
7665
7670
7675
7680
7685
7690
7695
7700
7705
7710
7715
7720
7725
7730
7735
7740
7745
7750
7755
7760
7765
7770
7775
7780
7785
7790
7795
7800
7805
7810
7815
7820
7825
7830
7835
7840
7845
7850
7855
7860
7865
7870
7875
7880
7885
7890
7895
7900
7905
7910
7915
7920
7925
7930
7935
7940
7945
7950
7955
7960
7965
7970
7975
7980
7985
7990
7995
8000
8005
8010
8015
8020
8025
8030
8035
8040
8045
8050
8055
8060
8065
8070
8075
8080
8085
8090
8095
8100
8105
8110
8115
8120
8125
8130
8135
8140
8145
8150
8155
8160
8165
8170
8175
8180
8185
8190
8195
8200
8205
8210
8215
8220
8225
8230
8235
8240
8245
8250
8255
8260
8265
8270
8275
8280
8285
8290
8295
8300
8305
8310
8315
8320
8325
8330
8335
8340
8345
8350
8355
8360
8365
8370
8375
8380
8385
8390
8395
8400
8405
8410
8415
8420
8425
8430
8435
8440
8445
8450
8455
8460
8465
8470
8475
8480
8485
8490
8495
8500
8505
8510
8515
8520
8525
8530
8535
8540
8545
8550
8555
8560
8565
8570
8575
8580
8585
8590
8595
8600
8605
8610
8615
8620
8625
8630
8635
8640
8645
8650
8655
8660
8665
8670
8675
8680
8685
8690
8695
8700
8705
8710
8715
8720
8725
8730
8735
8740
8745
8750
8755
8760
8765
8770
8775
8780
8785
8790
8795
8800
8805
8810
8815
8820
8825
8830
8835
8840
8845
8850
8855
8860
8865
8870
8875
8880
8885
8890
8895
8900
8905
8910
8915
8920
8925
8930
8935
8940
8945
8950
8955
8960
8965
8970
8975
8980
8985
8990
8995
9000
9005
9010
9015
9020
9025
9030
9035
9040
9045
9050
9055
9060
9065
9070
9075
9080
9085
9090
9095
9100
9105
9110
9115
9120
9125
9130
9135
9140
9145
9150
9155
9160
9165
9170
9175
9180
9185
9190
9195
9200
9205
9210
9215
9220
9225
9230
9235
9240
9245
9250
9255
9260
9265
9270
9275
9280
9285
9290
9295
9300
9305
9310
9315
9320
9325
9330
9335
9340
9345
9350
9355
9360
9365
9370
9375
9380
9385
9390
9395
9400
9405
9410
9415
9420
9425
9430
9435
9440
9445
9450
9455
9460
9465
9470
9475
9480
9485
9490
9495
9500
9505
9510
9515
9520
9525
9530
9535
9540
9545
9550
9555
9560
9565
9570
9575
9580
9585
9590
9595
9600
9605
9610
9615
9620
9625
9630
9635
9640
9645
9650
9655
9660
9665
9670
9675
9680
9685
9690
9695
9700
9705
9710
9715
9720
9725
9730
9735
9740
9745
9750
9755
9760
9765
9770
9775
9780
9785
9790
9795
9800
9805
9810
9815
9820
9825
9830
9835
9840
9845
9850
9855
9860
9865
9870
9875
9880
9885
9890
9895
9900
9905
9910
9915
9920
9925
9930
9935
9940
9945
9950
9955
9960
9965
9970
9975
9980
998

- 8 -

latter. In this embodiment the method comprises incubating the specimen with a reagent comprising 1) one or both glycoproteins of the invention (i.e. 61,000-68,000 and/or 46,000-52,000 d or immunocross-reactive polypeptides) and, optionally, 2) HTLV core proteins p24 or p19 or both, and determining whether or not an immunocomplex is formed between antibodies in the specimen and the reagent.

The elements necessary for carrying out the diagnostic methodology described hereinbefore may be present in a kit. Such kit comprises a carrier being compartmentalized to receive therein one or more containers, each of said containers comprising one or more elements necessary to carry out the tests.

For example, the first container may contain one or both of the purified glycoproteins or its immunologically cross-reactive polypeptides in detectably labelled or in insolubilized form.

A second container may comprise anti IgG antibody, polyclonal or monoclonal, useful in double antibody binding assay, or elements needed for detection of the label on the glycoprotein or its immunologically cross-reactive polypeptides (e.g. chromogenic substrates).

Additional containers may comprise varying amounts of one of the glycoproteins or its immunologically cross-reactive polypeptides which can be used to prepare a standard curve into which experimental results can be interpolated. The materials may be present in the kit by themselves, in solution, freeze-dried, or in admixture with other inert materials, such as inert proteins, and the like.

The biological specimens tested may include blood, serum, lymphocytes, urine, tissues, saliva,

- 9 -

feces, and the like. Of particular interest is the screening of blood in blood banks, to assure that the blood is not contaminated with HTLV. Screening of blood-derived products, such as vaccines, can also be done by the methods of the invention.

The following specific examples are intended to illustrate more fully the nature of the invention without acting as a limitation upon its scope.

Example 1

Preparation of Labelled Glycoprotein

A. Human T cell leukemia cells from the two cell lines MJ and C5-MJ were separately harvested at their log phase of growth. After one wash with methionine-free McCoy's 5A medium, each sample of the cells was resuspended in a labelling medium consisting of methionine-free McCoy's 5A, 10% phosphate-buffered saline (PBS), dialyzed fetal bovine serum, and 100 μ Ci/ml of 35 S-methionine. At the end of a 2 to 4 hour pulsing, the radioactive labelled cells were washed three times with cold PBS. The cell pellet was then lysed with 0.6 ml to 1.0 ml of cold lysis buffer (RIPA) (0.15 M sodium chloride, 0.05 M Tris-hydrochloride pH 7.2, 1% Triton X-100 wetting agent, 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate, and 1 mM phenylmethylsulfonyl fluoride). After 10 minutes of intermittent vortexing, the mix was centrifuged for 1 hour at 100,000 xg at 4°C. The lysate supernatant was precleared of nonspecific binding components by absorption for one hour at 4°C. on carbohydrate beads (Sephacrose CL-4B) coated with protein-A.

B. Labelling of cell surface membrane protein was carried out by lactoperoxidase catalyzed



- 10 -

radioiodination. Three aliquots of 5×10^6 cells of each line with greater than 99% viability were iodinated separately with 1 mCi of carrier-free sodium ^{125}I iodide in the presence of 50 μl carrier-supported lactoperoxidase and glucosidase (Enzymobeads, Bio-Rad Labs.) and 25 μl of 1% beta-D-glucose. After the reaction was terminated, three aliquots of iodinated cells were pooled and subjected to the same lysing and preclearing procedures as described in (A) above.

10 C. MJ and C5-MJ cells at their peak log phase of growth were separately harvested, then resuspended in glucose-free RPMI-1640 medium supplemented with 1 mg/ml of sodium pyruvate for 2 hours. After this glucose starvation, the cells were labelled with
15 100 $\mu\text{Ci/ml}$ of ^3H -glucosamine (New England Nuclear) for 5-6 hours. The procedure results in tritium labelling of only the glycoproteins present in the cells. The labelled cells were then subjected to lysing and preclearing procedures as described in (A) above.

20 Preparation of Labelled Unglycosylated Moiety of Glycoprotein

D. MJ and C5-MJ cells at their peak log phase of growth were separately harvested and resuspended in
25 McCoy's 5A medium supplemented with 10% fetal bovine serum, 1% of antibiotic-antimycotic mixture, and 20 $\mu\text{g/ml}$ of tunicamycin for 2 hours. After this trimming step, the cells were labelled with 100 $\mu\text{Ci/ml}$ of ^{35}S -methionine in the presence of 20 $\mu\text{g/ml}$ of
30 tunicamycin for 2 hours. The labelled material was then subjected to the same lysing and preclearing procedures as described in (A) above.



- 11 -

Formation of Protein-Antibody Complex

5 E. There were bound to aliquots of protein-A-coated beads (a) positive reference blood serum for individual known to harbor antibodies against cells infected with HTLV; (b) negative control serum
10 from individuals free from infection; and (c) serum from unknown individuals to be tested. Each aliquot of coated beads was then reacted with an aliquot of each precleared lysate obtained from MJ and from C5-MJ from paragraph (A) above at 4°C. for 1-2 hours to permit complex formation or immunoprecipitation to occur between the bonded lysate protein and any antibody present in the sera. At the end of the reaction the beads were washed 4 times with the buffer (RIPA) and
15 once with a buffer containing 0.05 M Tris-hydrochloride pH 7.2 and 0.15 M sodium chloride to remove uncomplexed lysate protein.

The beads were then immersed in a sample buffer (0.1 M Cleland's reagent, 2% sodium
20 dodecylsulfate, 0.08 M Tris-hydrochloride pH 6.8, 10% glycerol, and 0.2% Bromphenol Blue) and subjected to boiling at 100°C. for 2 minutes to elute proteins from the beads and to dissociate complexes.

Characterization of Protein

25 F. Each sample from the foregoing procedure (A) was analyzed by electrophoresis, the proteins being separated on a 12.5% SDS-polyacrylamide gel with 3.5% stacking gel using the Laemmli buffer system. Molecular weight markers were run simultaneously in a parallel column. The markers used included
30 ¹⁴C-labelled phosphorylase b (92,500), bovine serum albumin (68,000), and ovalbumin (46,000) carbonic anhydrase (30,000) and cytochrome C (12,000). For



- 12 -

5 visualization by fluorography, the gels were first fixed with 10% acetic acid, 10% trichloroacetic acid, and 30% methanol for 1 hour, then immersed in Enhancer solution for 1 hour. After rinsing with distilled water and drying under vacuum, the gels were exposed on Kodak SB-5 film to provide autoradiographs.

10 The spots of purified and isolated 61,000-68,000 molecular weight glycoprotein and of 45,000-52,000 molecular weight glycoprotein appeared prominently in all of the columns of serum (a), but in none of those of serum (b). In contrast, the core proteins p19 and p24 failed to appear in all samples of serum (a). Appearance of the glycoprotein in the unknown sera (c) indicated the presence in the sera of
15 cells infected with HTLV. Sera from individuals exhibiting AIDS also exhibited prominent evidence of antibodies to the 61,000-68,000 MW glycoprotein in this procedure.

20 Similar results have been obtained by substituting for the labelled glycoproteins of paragraph A, either of those of paragraphs B or C. There could also be substituted for it the labelled unglycosylated moiety of paragraph D, in which case the purified and isolated labelled moiety appears in the
25 gel column at a location corresponding to molecular weight 46,000-48,000. Unlabelled glycoprotein and unlabelled unglycosylated moiety can be obtained by omitting the labelling steps in the foregoing procedures.

30 Similar results have been obtained by substituting cell lines C91PL or HUT-102 in place of MJ or C5MJ.



- 13 -

Amino Acid Sequence Analysis. [^{35}S]cysteine-labeled glycoproteins having a molecular weight of approximately 61,000 daltons and of approximately 45,000-46,000 daltons, respectively, were precipitated from 36×10^6 Hut 102 cells metabolically labeled with 5mCi of [^{35}S]cysteine (specific activity 1011.2Ci/mmol, New England Nuclear) in 30 ml of cysteine-free RPMI-1640 media containing 15% fetal bovine serum (Grand Island Biological Co.) for 10 hours. The two glycoproteins were excised from NaDodSO₄ polyacrylamide gels and then individually subjected to electrophoretic elution in the presence of 50mM Tris-acetate pH 7.8 buffer containing 0.01% NaDodSO₄ for 12-16 hours. Samples were dialyzed once with 10mM of ammonium bicarbonate buffer containing 0.002% NaDodSO₄ for 12-16 hours. One more dialysis was done with 10mM ammonium bicarbonate buffer without NaDodSO₄ for 12-16 hours. Each sample was then lyophilized and amino acid sequence analysis was conducted by the procedures described by Coligan et al., J. Immun. Meth., Vol. 47, 1-11 (1981) and Meth. Enzymol., Vol. 91, 413-434 (1983). Briefly, automated Edman degradation of radiolabeled peptides was performed utilizing a Beckman 890C sequencer with cold trap modification and 0.1 M Quadrol program 121078. The butyl chloride extract from each sequence step was dried using N₂ evaporation in 7.0 ml scintillation vials. After addition of Biofluor (NEN), radioactivity was determined on a Beckman LS9080 liquid scintillation counter. [^{35}S] peaks were found at residues 6, 7, 21 and 28, indicating the presence of cysteine at these positions in the protein sequence of the 61,000-68,000 d glycoprotein. The repetitive yield for this

NAL



- 14 -

sequence was 88%, indicating that all the residues are in the same sequence. Small peaks at positions 4 and 13 are presumably from small amounts (less than 5%) of contaminating proteins. These results indicate that
5 the 61,000-68,000 mw glycoprotein is encoded, at least in part, by the env gene of HTLV and that the leader sequence of the env gene consists of 20 residues.

Similar analysis was carried out with [³⁵S] cysteine labeled glycoproteins having molecular weights
10 of approximately 67,000 d and 50,000-52,000 d respectively. Cysteine residues were detected at positions 6, 7 and 21 when the first 22 NH₂-terminal residues were analyzed. This shows that this glycoprotein is also encoded, at least in part, by the
15 same NH₂-terminal end of the env gene.

What is claimed is:



- 15 -

1 1. A substantially pure polypeptide having an
2 antigenic determinant or determinants immunologically
3 cross-reactive with the determinants of a glycoprotein
4 having a molecular weight of approximately 61,000-
5 68,000 daltons, of which approximately 46-48,000
6 daltons is the molecular weight of the unglycosylated
7 moiety or of a glycoprotein having a molecular weight
8 of approximately 45,000-52,000 daltons, said
9 glycoproteins being present on the cell surface of
10 cells infected with human T-cell leukemia virus.

1 2. The polypeptide of claim 1 which is the
2 HTLV-associated cell surface glycoprotein of claim 1.

1 3. A polypeptide as claimed in claim 1 which
2 comprises the unglycosylated moiety of the
3 HTLV-associated cell surface glycoprotein of claim 1.

1 4. A polypeptide as claimed in claim 1 in
2 which said glycoprotein is present on the cell surface
3 of human T-cell leukemia cell lines CRL-8294 or
4 CRL-8293.

1 5. A polypeptide as claimed in claims 2 or 3
2 which is obtained from MJ, C5-MJ, C91PL or HUT-102
3 cells.

1 6. A polypeptide as claimed in claim 1 which
2 comprises an anti-idiotypic antibody having antigenic
3 determinants which are immunologically cross-reactive
4 with those of said glycoprotein. , i.e. use of the anti-idiotyp
Ab as an "antigen"

NAL



- 16 -

1 7. A polypeptide as claimed in claim 1 which
2 comprises an anti-idiotypic antibody having antigenic
3 determinants which are immunologically cross-reactive
4 with those of said glycoproteins.

1 8. A polypeptide as claimed in any of
2 claims 1, 2, 3, 4, 6 or 7 which is detectably labelled.

1 9. The polypeptide of claim 8 wherein said
2 label is selected from the group consisting of a
3 radiolabel, a fluorogenic label, an enzyme label or a
4 biotin label.

1 10. The polypeptide of any of claims 1, 2, 3,
2 or 4 which is bound to an insoluble phase.

1 11. The polypeptide of claim 10 wherein said
2 solid phase is a latex particle or an insoluble resin.

1 12. A process for preparing the glycoprotein
2 of claim 2 which comprises culturing MJ or C5-MJ cells
3 under appropriate culturing conditions, and
4 extracting said glycoprotein from said cells.

1 13. The substantially unglycosylated moiety
2 of a glycoprotein having a molecular weight of
3 approximately 61,000-68,000 daltons of which
4 approximately 46,000-48,000 daltons is the
5 unglycosylated moiety, which glycoprotein occurs on the
6 cell surface of cells infected with HTLV.

1 14. The moiety as claimed in claim 13 which is
2 detectably labelled.



- 17 -

1 15. The moiety as claimed in claim 13 which
2 is bound to an insoluble phase.

1 16. The method of assaying a biological
2 specimen for the presence of antibody to HTLV-infected
3 cells which comprises
4 incubating said specimen with a polypeptide
5 having an antigenic determinant or determinants
6 immunologically cross-reactive with the determinants of
7 a glycoprotein having a molecular weight of
8 approximately 61,000-68,000 daltons, of which
9 approximately 46-48,000 daltons is the molecular weight
10 of the unglycosylated moiety or of a glycoprotein
11 having a molecular weight of approximately
12 45,000-52,000 daltons, said glycoproteins being present
13 on the cell surface of cells infected with human T-cell
14 leukemia virus, and claimed in claim 1, and
15 determining whether or not an immunocomplex is
16 formed between said antibody and said polypeptide.

1 17. The method as claimed in claim 16 in
2 which said polypeptide is said glycoprotein having a
3 molecular weight of approximately 61,000-68,000 daltons.

1 18. The method as claimed in claim 16 in
2 which said polypeptide is said unglycosylated moiety
3 having a molecular weight of approximately
4 46,000-48,000 daltons.

1 19. The method as claimed in claim 16 in
2 which said polypeptide is said glycoprotein having a
3 molecular weight of approximately 45,000-52,000 daltons.



- 18 -

1 20. The method as claimed in any of claims
2 16-19 including the step of labelling said polypeptide.

1 21. The method as claimed in any of claims
2 16-19 which is an enzyme linked immunoassay.

1 22. The method as claimed in any of claims
2 16-19 which is a radioimmunoassay.

1 23. The method as claimed in any of claims
2 16-19 which is a latex particle agglutination assay.

1 24. The method as claimed in any of claims
2 16-19 which is a fluorescence assay.

1 25 The method as claimed in any of claims
2 16-19 which is a double antibody immunoassay.

1 26. A method of detecting the presence in a
2 biological specimen of an antigenic determinant or
3 determinants immunologically cross-reactive with those
4 of the polypeptide claimed in claim 1 which comprises:
5 incubating said specimen with antibodies
6 against the polypeptide of claim 1, and
7 determining whether or not an immunocomplex is
8 formed between said antibodies and said polypeptides.

1 27. The method as claimed in claim 26 wherein
2 said specimen comprises human lymphocytes.

1 28. The method as claimed in claim 26 wherein
2 said antibodies are against said glycoprotein having a
3 molecular weight of 61,000-68,000 daltons.



- 19 -

1 29. The method as claimed in claim 26 wherein
2 said antibodies are against the unglycosylated moiety
3 of said glycoprotein having molecular weight of 61,000-
4 68,000.

1 30. The method as claimed in claim 26 wherein
2 said antibodies are against a glycoprotein having
3 molecular weight of approximately 46,000-55,000 which
4 glycoprotein occurs on the cell surface of cells
5 infected with HTLV.

1 31. The method as claimed in claim 26 wherein
2 said antibodies are against a glycoprotein which occurs
3 on the cell surface of MJ or C5-MJ cells.

1 32. A kit useful for assaying a sample for
2 the presence of antibody to HTLV-infected cells, said
3 kit being compartmentalized to receive in close
4 confinement therein one or more containers which
5 comprises

6 a first container containing the polypeptide
7 of any of claims 1, 2, 3, 4, 6 or 7

8 a second container containing means for
9 detecting the formation of an immunocomplex between
10 said antibody and said polypeptide.



INTERNATIONAL SEARCH REPORT

International Application No. **PCT/US84/00561**

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) *		
According to International Patent Classification (IPC) or to both National Classification and IPC		
I.P.C.	C12N 7/06	G01N 33/54
II. FIELDS SEARCHED		
Minimum Documentation Searched *		
Classification System	Classification Symbols	
	260/112R 424/1.1, 86, 89	
	435/4, 5, 7, 68, 70, 235, 238, 239, 800	
U.S.C.	436/518, 528, 531, 533, 536, 540, 542-546, 800, 804, 808, 811	
Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched		
III. DOCUMENTS CONSIDERED TO BE RELEVANT **		
Category *	Citation of Document, ** with indication, where appropriate, of the relevant passages **	Relevant to Claim No. **
A	N, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, USA, VOLUME 77, PAGES 7415-7419, ISSUED DECEMBER 1980, POIESZ, B.J. ET AL, DETECTION AND ISOLATION OF TYPE C RETROVIRUS PARTICLES FROM FRESH AND CULTURED LYMPHOCYTES OF A PATIENT WITH CUTANEOUS T-CELL LYMPHOMA.	1-32
X	N, JOURNAL OF VIROLOGY, VOLUME 38, PAGES 906-915, ISSUED JUNE 1981, KALYANARAMAN, V. S. ET AL, IMMUNOLOGICAL PROPERTIES OF A TYPE C RETROVIRUS ISOLATED FROM CULTURED HUMAN T-LYMPHOMA CELLS AND COMPARISON TO OTHER MAMMALIAN RETROVIRUSES.	1-32
X	N, JOURNAL OF EXPERIMENTAL MEDICINE, VOLUME 154, PAGES 333-346, ISSUED AUGUST 1981, POSNER, L.E. ET AL, NATURAL ANTIBODIES TO THE HUMAN T CELL LYMPHOMA VIRUS IN PATIENTS WITH CUTANEOUS T CELL LYMPHOMAS.	1-32
X	N, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, USA, VOLUME 78, PAGES 6476-6480.	1-32
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>* Special categories of cited documents: **</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"G" document member of the same patent family</p> </div> </div>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search *	Date of Mailing of this International Search Report *	
18 MAY 1984	11 JUN 1984	
International Searching Authority *	Signature of Authorized Officer	
ISA/US	M.N. <i>E. R. PADGETT</i>	

II. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, ¹⁰ with indication, where appropriate, of the relevant passages ¹¹	Relevant to Claim No. ¹²
X	ISSUED OCTOBER 1981, HINUMA, Y. ET AL, ADULT T-CELL LEUKEMIA: ANTIGEN IN AN ATL CELL LINE AND DETECTION OF ANTIBODIES TO THE ANTIGEN IN HUMAN SERA.	
X	N, NATURE, VOLUME 294, PAGES 271-273, ISSUED NOVEMBER 1981, KALYANARAMAN, V.S. ET AL, ANTIBODIES IN HUMAN SERA REACTIVE AGAINST AN INTERNAL STRUCTURAL PROTEIN OF HUMAN T-CELL LYMPHOMA VIRUS.	1-32
X	N, NATURE, VOLUME 294, PAGES 268-271, ISSUED NOVEMBER 1981, POIESZ, B.J. ET AL, ISOLATION OF A NEW TYPE C RETROVIRUS (HTLV) IN PRIMARY UNCULTURED CELLS OF A PATIENT WITH SEIZARY T-CELL LEUKAEMIA.	1-32
X	N, JOURNAL OF EXPERIMENTAL MEDICINE, VOLUME 154, PAGES 1957-1964, ISSUED DECEMBER 1981, ROBERT-GUROFF, M. ET AL, DETECTION OF THE HUMAN T CELL LYMPHOMA VIRUS p19 IN CELLS OF SOME PATIENTS WITH CUTANEOUS T CELL LYMPHOMA AND LEUKEMIA USING A MONOCLONAL ANTIBODY.	1-32
X	N, SCIENCE, VOLUME 215, PAGES 975-978, ISSUED FEBRUARY 1982, ROBERT-GUROFF, M. ET AL, NATURAL ANTIBODIES TO HUMAN RETROVIRUS HTLV IN A CLUSTER OF JAPANESE PATIENTS WITH ADULT T CELL LEUKEMIA.	1-32
Y	N, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, USA, VOLUME 79, PAGES 1291-1294, ISSUED FEBRUARY 1982, OROSELAN, S. ET AL, PRIMARY STRUCTURE ANALYSIS OF THE MAJOR INTERNAL PROTEIN p24 OF HUMAN TYPE C T-CELL LEUKEMIA VIRUS.	1-32
X	N, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, USA, VOLUME 79, PAGES 2031-2035, ISSUED MARCH 1982, YOSHIDA, M. ET AL, ISOLATION AND CHARACTERIZATION OF RETROVIRUS FROM CELL LINES OF HUMAN ADULT T-CELL LEUKEMIA AND ITS IMPLICATION IN THE DISEASE.	1-32
Y	N, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, USA, VOLUME 79, PAGES 1653-1657, ISSUED MARCH 1982, NATURAL ANTIBODIES TO THE STRUCTURAL CORE PROTEIN (p24) OF THE HUMAN T-CELL LEUKEMIA (LYMPHOMA) RETROVIRUS FOUND IN SERA OF LEUKEMIA PATIENTS IN JAPAN.	1-32
X	N, JOURNAL OF THE NATIONAL CANCER INSTITUTE, VOLUME 69, PAGES 981-985, ISSUED OCTOBER 1982, ESSEX, M., ADULT T-CELL LEUKEMIA-LYMPHOMA: ROLE OF A HUMAN RETROVIRUS.	1-32

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, ¹⁴ with indication, where appropriate, of the relevant passages ¹⁷	Relevant to Claim No. ¹⁸
X	N, VIROLOGY, VOLUME 122, PAGES 297-305, ISSUED OCTOBER 1982, ROBERT-GUROFF, M. ET AL, IDENTIFICATION OF HTLV p19 SPECIFIC NATURAL HUMAN ANTIBODIES BY COMPETITION WITH MONOCLONAL ANTIBODY.	1-32
X	N, SCIENCE VOLUME 218, PAGES 571-573, ISSUED NOVEMBER 1982, KALYANARAMAN, V.S. ET AL, A NEW SUBTYPE OF HUMAN T-CELL LEUKEMIA VIRUS (HTLV-II) ASSOCIATED WITH A T-CELL VARIANT OF HAIRY CELL LEUKEMIA.	1-32
Y	N, SCIENCE, VOLUME 220, PAGES 856-859, ISSUED FEBRUARY 1983, POPOVIC, M. ET AL, ISOLATION AND TRANSMISSION OF HUMAN RETRO-VIRUS (HUMAN T-CELL LEUKEMIA VIRUS).	1-32
Y,P	N, SCIENCE, VOLUME 220, PAGES 859-862, ISSUED MAY 1983, ESSIX, M. ET AL, ANTIBODIES TO CELL MEMBRANE ANTIGENS ASSOCIATED WITH HUMAN T-CELL LEUKEMIA VIRUS IN PATIENTS WITH AIDS.	1-32
Y,P	N, SCIENCE, VOLUME 220, PAGES 865-867, ISSUED MAY 1983, GALLO, R.C. ET AL, ISOLATION OF HUMAN T-CELL LEUKEMIA VIRUS IN ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS).	1-32
Y,P	N, SCIENCE, VOLUME 220, PAGES 868-871, ISSUED MAY 1983, BARRE-SINOUSS I,F. ET AL, ISOLATION OF A T-LYMPHOTROPIC RETROVIRUS FROM A PATIENT AT RISK FOR ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS).	1-32
Y,P	N, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, USA, VOLUME 80, PAGES 3618-3622, ISSUED JUNE 1983, SEIKI, M. ET AL, HUMAN ADULT T-CELL LEUKEMIA VIRUS: COMPLETE NUCLEOTIDE SEQUENCE OF THE RETROVIRUS GENOME INTEGRATED IN LEUKEMIA CELL DNA.	1-32
Y,P	N, SCIENCE, VOLUME 223, PAGES 1083-1086, ISSUED MARCH 1984, MARX, P.A. ET AL, SIMIAN AIDS: ISOLATION OF A TYPE D RETRO-VIRUS AND TRANSMISSION OF THE DISEASE.	1-32
Y,P	N, JOURNAL OF EXPERIMENTAL MEDICINE, VOLUME 159, PAGES 1117-1131, ISSUED APRIL 1984, PALKER, T.J. ET AL, MONOCLONAL ANTIBODIES AGAINST HUMAN T CELL LEUKEMIA-LYMPHOMA VIRUS (HTLV) p24 INTERNAL CORE PROTEIN.	1-32